

Gujarat Kidney & Super Speciality Ltd.

'SUBSCRIBE'

22-12-2025 TO 24-12-2025

Industry: Healthcare services

Price Band: ₹108 to ₹114

Recommendation: Subscribe for long term

Post Implied Market Cap: ₹852 Cr – ₹899 Cr

Key Data

Issue Size (₹ Cr)	₹250.80
Fresh (₹ Cr)	₹250.80
OFS (₹ Cr)	-
No of shares offered (total issue)	2,20,00,000
Face Value (₹ /share)	2
Bid Lot	128 Shares

Indicative Timetable

IPO Open Date	Mon, Dec 22, 2025
IPO Close Date	Wed, Dec 24, 2025
Tentative Allotment	Fri, Dec 26, 2025
Initiation of Refunds	Mon, Dec 29, 2025
Credit of Shares to Demat	Mon, Dec 29, 2025
Tentative Listing Date	Tue, Dec 30, 2025
Cut-off time for UPI mandate confirmation	5 PM on Wed, Dec 24, 2025

Shareholding (No. of shares)

Pre-Issue	5,68,43,250
Post-Issue	7,88,43,250

Issue Breakup

QIB	75%
NII	15%
Retail	10%

Shareholding Pattern

	Promoter	Public
Pre-Issue	99.10%	0.90%
Post-Issue	71.45%	28.55%

Other Details

BRLM: Nirbhay Capital Services Private Limited

Registrar: MUFG Intime India Private Limited

(Formerly Link Intime India Private Limited)

Listing: BSE & NSE

Research Analyst

Anshul Jain
Anshul.trader@icloud.com
8767231444

About the company

Gujarat Kidney and Super Speciality Ltd. is a Gujarat based healthcare group focused on kidney care and multi-speciality services, operating around seven mid-sized hospitals and in-house pharmacies with roughly 490 beds (about 340 operational) across cities like Vadodara, Godhra, Bharuch, Borsad and Anand, and offering integrated secondary and tertiary care in nephrology, urology, orthopaedics, cardiology, joint replacement, obstetrics, critical care, diagnostics and pharmacy at affordable prices for semi-urban and urban patients.

Investment Rationales

Niche Specialization: High-entry-barrier focus on renal sciences (Nephrology and Urology) ensures a "sticky" patient base with recurring needs (like dialysis), creating steady, defensive revenue.

Efficient Scalability: The "asset-light" roll-up strategy (acquiring and leasing existing hospitals) minimizes the 4–5 year build-from-scratch delay, allowing immediate bottom-line contributions.

Strong Financials: The company achieved 637% revenue growth (FY24 to FY25) with sector-leading efficiency converting to an EBITDA margin of 41.12% and a ROCE of 37.65%.

Growth-Focused IPO: The ₹250.80 crore issue is 100% Fresh Issue with zero promoter exit (OFS), meaning all capital is strictly deployed for expanding capacity and tech like robotic surgery.

Regional Dominance: Strong concentration in Tier-2/3 Gujarat cities (Vadodara, Bharuch, Godhra) provides a competitive opportunity in underserved markets where national corporate chains have minimal presence.

Risk

Revenues are significantly concentrated to Gujarat Kidney hospital in Vadodara, attributing to 29% in FY25.

Highly dependent on healthcare professionals including doctors and nurses.

Our views

Gujarat Kidney and Super Speciality Limited has grown its scale and profitability on the back of an asset-heavy but efficient hospital model, with improving margins driven by better case mix, higher occupancy, and operating leverage from its existing infrastructure.

The entire ₹250.80 Cr (100%) IPO is a Fresh Issue, with Zero Offer for Sale (OFS), signalling strong promoter confidence. Approximately ₹77 Cr is earmarked for the landmark acquisition of Parekhs Hospital in Ahmedabad, while ₹30 Cr will fund a new greenfield Women's Hospital in Vadodara. Additional funds are allocated for robotic surgical equipment and increasing stakes in high-performing subsidiaries.

Despite the competitive nature of the healthcare sector, Gujarat Kidney's asset-light integration model and its dominance in the renal care niche allow it to capitalize on the rising demand for quality healthcare in semi-urban India. We recommend a 'SUBSCRIBE' rating for long term investors.

CONSOLIDATED FINANCIALS – BASIC FINANCIAL DETAILS

Financial & Operating Performance Indicators	Unit	Fiscal 2023	Fiscal 2024	Fiscal 2025
Total Bed Capacity	in number	439	539	539
Approved Beds	in number	369	494	494
Operational Beds	in number	339	389	389
ICU Beds	in number	70	80	80
IPD Volume	Number of patients	11238	12733	13281
IPD Revenue	₹ Cr	62.74	71.94	81.72
OPD Volume	Number of patients	76869	91264	95876
OPD Revenue	₹ Cr	10.40	13.60	16.22
Revenue from Operations	₹ Cr	85.79	103.44	119.97
Bed Days Occupied		67428.00	76398.00	79686.00
Average Bed Occupancy Rate	%	54.49%	53.81%	56.12%
Average Revenue per Occupied Bed	₹	9304.77	9416.71	10255.39
Average length of stay in hospitals (ALOS)		6	6	6

data based on unaudited pro forma consolidated financial statements

Source: Company RHP

Gujarat Kidney & Super Speciality Ltd. IPO Peer Comparison

(As on March 31, 2025)

Company Name	EPS (Basic)	EPS (Diluted)	NAV (per share) (Rs)	P/E (x)	RoNW (%)	P/BV Ratio	Financial statements
Gujarat Kidney & Super Speciality Limited	1.85	1.85	5.04	61.62	36.61		Consolidated
Yatharth Hospital & Trauma Care Services Ltd	14.72	14.83	88.05	55.84	8.13	9.34	Consolidated
Gpt Healthcare Limited	6.08	12.26	40.71	24.51	20.14	3.73	Standalone
Kmc Speciality Hospitals (india) Ltd	1.31	9.25	23.16	52.6	13.04	3	Standalone

Notes:

The Company, the information above is based on the Restated Consolidated Financial Statements.

All the financial information for listed industry peers mentioned above is on a consolidated basis and has been sourced from the annual reports/annual results as available of the respective company for the year ended March 31, 2025 submitted to stock exchanges.

Current market price (CMP) is the closing market price of the equity shares of the respective companies on NSE on November 4, 2025.

Diluted EPS refers to the diluted earnings per share sourced from the annual reports/annual results as available of the respective company for the year ended March 31, 2025 submitted to stock exchange.

P/E Ratio for Gujarat Kidney & Super Speciality Ltd. is implied and not actual.

Disclaimer & Disclosure

This Report is published by Lakshmishree Investment & Securities Limited (hereinafter referred to as "LISL") for registered client circulation only. LISL is a registered Research Analyst under SEBI (Research Analyst) Regulations, 2014 having Registration no. INH00014395. LISL is a registered broker with the Securities & Exchange Board of India (SEBI) and registered with National Stock Exchange of India Limited and BSE Limited in cash and derivatives segments, Multi Commodity Exchange of India (MCX), and is Depository participant with Central Depository Services Limited (CDSL), and also member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

LISL a "Research Entity" under SEBI (Research Analyst) Regulations 2014 has independent research teams working with a Chinese wall rule with other business divisions of LISL as mentioned above.

LISL or its associates have not been debarred / suspended by SEBI or any other regulatory authority for accessing / dealing in securities Market. LISL, its associates or Research analyst or his relatives do not hold any financial interest in the subject company. LISL or its associates or Research analysts do not have any conflict or material conflict of interest at the time of publication of the research report with the subject company. LISL or its associates or Research Analyst or his relatives do not hold beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of this research report.

LISL or its associates or Research analyst has not received any compensation / managed or co-managed public offering of securities of the company covered by Research analyst during the past twelve months. LISL or its associates have not received any compensation or other benefits from the company covered by Research analyst or third party in connection with the research report. Research Analyst has not served as an officer, director or employee of Subject Company and LISL / Research analyst has not been engaged in market making activity of the subject company.

This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. LISL is not soliciting any action based upon it. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any such transaction. In preparing this research, we did not take into account the investment objectives, financial situation and particular needs of the reader. This research has been prepared for the general use of the clients of LISL and must not be copied, either in whole or in part, or distributed or redistributed to any other person in any form. If you are not the intended recipient you must not use or disclose the information in this research in any way. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. LISL will not treat recipients as customers by virtue of their receiving this report. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject LISL & its group companies to registration or licensing requirements within such jurisdictions.

The report is based on the information obtained from sources believed to be reliable, but we do not make any representation or warranty that it is accurate, complete or up-to date and it should not be relied upon as such. We accept no obligation to correct or update the information or opinions in it. LISL or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. LISL or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

This information is subject to change without any prior notice. LISL reserves its absolute discretion and right to make or refrain from making modifications and alterations to this statement from time to time. Nevertheless, LISL is committed to providing independent and transparent recommendations to its clients, and would be happy to provide information in response to specific client queries.

Before making an investment decision on the basis of this research, the reader needs to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of their particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. Opinions expressed are subject to change without any notice. Neither the company nor the director or the employees of LISL accept any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Here it may be noted that neither LISL, nor its directors, employees, or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profit that may arise from or in connection with the use of the information contained in this report.

Analyst Certification: Research Analyst the author of this report, hereby certify that the views expressed in this research report accurately reflects my personal views about the subject securities, issuers, products, sectors or industries. It is also certified that no part of the compensation of the Research Analyst was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research. The Research Analyst is principally responsible for the preparation of this research report and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

CIN No U74110MH2005PLC157942 | BSE-3281 | NSE-12817 | MCX-55910 | DP:IN-DP-CDSL-490-2008 | DPID:12059100 |

SEBI Regn. No.: INZ000170330 | Mutual Fund: ARN-77739 | Research Analyst: INH000014395

Registered Office:

Unit No 407, IV Floor, Marathon Icon, Ganpat Rao Kadam Marg, Lower Parel West, Mumbai 400013
Contact No: (022) 43431818

Corporate Office:

Shree House C-29/61-5 Teliyabag Varanasi, UP 221002
Contact No: (0542) 6600000

Email: info@lakshmishree.com, Website: www.lakshmishree.com
Compliance Officer: Abhishek Sharma
Email Id: compliance@lakshmishree.com
Phone No +91 92353 95868